Research

We are dedicated to providing access to clinical trials and invest in research across our cancer centres, helping to provide hope and contribute to breakthroughs and advancements in cancer treatments.

Overview

Icon Group has almost 30 years’ experience in cancer research and now operates the largest private cancer clinical trials program in Australia. As part of Icon Group, Icon Cancer Centre  Singapore is committed to providing access to research and clinical trials to patients across ASEAN.

We believe patients across our centres deserve the opportunity to access clinical trials and the hope that they offer.

To find out more about the research that Icon is participating in, our team and achievements during 2023, please read the 2023 Icon Research Annual Report.

What clinical trials does Icon offer?

At Icon, our dedicated research program enables our patients to access new and emerging advances in cancer treatment, giving new hope and opportunities to patients and their families.

We run trials across various tumour types and haematological conditions, including chemotherapy, immunotherapy and radiation therapy trials. Icon also offers trials that aren’t directly connected to a treatment technique, but are focused on wellbeing and improving quality of life for our patients.

By providing access to a wide range of clinical trials across a multitude of cancer types, Icon helps to contribute to breakthroughs and advancements in cancer treatments for the benefit of current and future patients.

Express your interest

If you are interested in taking part in a clinical trial, we are here to help you understand your options.
Learn more

Our global research

Icon operates Australia’s largest private cancer clinical trials program with a growing reach globally. Learn more about our impact to date.
Learn more

Doing research with us

For industry partners interested in working with us on collaborative research or clinical trials please visit Icon Group.
Learn more

Anda dialihkan ke laman berbahasa Inggris karena isi dari laman ini belum diterjemahkan.

Cari